Journal
ACTA HAEMATOLOGICA
Volume 138, Issue 4, Pages 216-220Publisher
KARGER
DOI: 10.1159/000484515
Keywords
Diffuse large B-cell lymphoma; Lenalidomide; Maintenance treatment
Categories
Ask authors/readers for more resources
Diffuse large B-cell lymphoma is an aggressive non-Hodgkin lymphoma subtype which requires immediate treatment. Standard treatment is usually a combined immune chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Since R-CHOP was approved, several attempts to combine it with novel agents and/or use them as maintenance therapy failed to improve the outcome. Recently, maintenance with lenalidomide after standard immune chemotherapy showed promising results. This review discusses the most pertinent published and running studies, analyzing study design, results, and practicality. (C) 2017 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available